EMA Authorised: Fampyra (Fampridine) — Merz Therapeutics GmbH

View source ↗

Summary

The EMA authorised Fampyra (fampridine) by Merz Therapeutics GmbH for multiple sclerosis, confirming its use to improve walking in patients with MS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fampyra (fampridine)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Merz Therapeutics GmbH. Decision date: 06/08/2025